You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

78 Results
Guidelines and Advice
Jul 2017
Guidelines and Advice
Jul 2017
Guidelines and Advice
Status: Current
ID: GL 4-1
Version: 2
Jan 2021
Guidelines and Advice
Status: Current
ID: ES 30-1
Mar 2021
Guidelines and Advice
Status: Archived
ID: 2-14
Version: 3
Apr 2011
Guidelines and Advice
Status: Archived
ID: 1-4
Sep 2012
Guidelines and Advice
Status: In-Review
ID: GL 2-24
May 2019
Guidelines and Advice
Status: Current
ID: N/A
Version: 2
Jan 2023
Symptom Management
Symptom Management
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab and Relatlimab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab / relatlimab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Mar 2026
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab,
ipilimumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet
Updated
Mar 2026

Pages